pre-IPO PHARMA

COMPANY OVERVIEW

Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder.


LOCATION

  • Plymouth Meeting, PA, USA

  • THERAPEUTIC AREAS

  • Pain

  • WEBSITE

    https://braeburnrx.com/


    CAREER WEBSITE

    https://braeburnrx.com/careers/


    SOCIAL MEDIA


    INVESTORS

    apple-tree-partners avista-capital-partners deerfield-management new-leaf-capital-partners ra-capital rock-springs-capital wellington-management-company


    PRESS RELEASES


    Oct 14, 2022

    NLRB to Prosecute Braeburn Alloy Steel over Unfair Labor Practices


    Jun 26, 2021

    FDA Accepts Braeburn's New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder


    Jun 15, 2021

    Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder


    Jun 15, 2021

    Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US


    Dec 10, 2020

    Braeburn Announces Arbitration Determination that It Did Not Materially Breach Its License Agreement with Camurus AB


    For More Press Releases


    Google Analytics Alternative